Description

Drug Class:

Tigecycline belongs to the glycylcycline class of antibiotics, representing a significant advancement in the treatment of multidrug-resistant bacterial infections. With its unique mechanism of action and broad-spectrum activity, tigecycline is highly effective against a wide range of Gram-positive and Gram-negative pathogens.

Formulation:

• Tigecycline General Dry Powder for Injection: Each vial contains 50mg of tigecycline in the form of a dry powder for reconstitution. This formulation ensures stability, potency, and ease of administration, making it suitable for the treatment of severe infections where intravenous therapy is necessary.

Indications:

Tigecycline is indicated for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP) caused by susceptible pathogens, 

including:

• Methicillin-resistant Staphylococcus aureus (MRSA)
• Vancomycin-resistant Enterococcus (VRE)
• Extended-spectrum beta-lactamase (ESBL)-producing organisms
• Acinetobacter baumannii
• Klebsiella pneumoniae
• Escherichia coli

Usage:

• Tigecycline General Dry Powder for Injection is intended for intravenous use only and should be administered by healthcare professionals experienced in the management of serious infections.
• Prior to administration, the dry powder must be reconstituted with a suitable diluent according to the manufacturer’s instructions.
• The infusion rate and duration of treatment should be determined based on the severity of the infection, the patient’s condition, and the susceptibility of the causative pathogen.

Dosage:

• The recommended dosage of tigecycline is an initial dose of 100mg administered intravenously, followed by 50mg every 12 hours.
• Dosage adjustments may be necessary in patients with hepatic impairment or severe renal impairment. Consult the prescribing information for specific dosing guidelines.

Side Effects:

• Common side effects of tigecycline may include:
  • Nausea
  • Vomiting
  • Diarrhea
  • Headache
  • Dizziness
  • Elevated liver enzymes
• Serious adverse effects such as hepatotoxicity, hypersensitivity reactions, and Clostridioides difficile-associated diarrhea (CDAD) may occur and require prompt medical attention.

Packing Specifications:

Tigecycline General Dry Powder for Injection is meticulously packaged in single-dose vials, with each vial containing 50mg of tigecycline. This packaging format ensures product integrity, sterility, and convenience for healthcare professionals during administration.

Experience the unparalleled efficacy and versatility of AIT Pharmaceuticals Division’s Tigecycline Range in the treatment of serious bacterial infections. For more information, please contact us.